Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.

Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, Han SY, Li G, Jensen KC, Vogel H, Xu LW, Skirboll SS, Wong AJ.

Cancer Res. 2014 Feb 15;74(4):1238-49. doi: 10.1158/0008-5472.CAN-13-1407. Epub 2013 Dec 23.

2.

A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.

Liu XJ, Wu WT, Wu WH, Yin F, Ma SH, Qin JZ, Liu XX, Liu YN, Zhang XY, Li P, Han S, Liu KY, Zhang JM, He QH, Shen L.

CNS Neurosci Ther. 2013 Jul;19(7):494-502. doi: 10.1111/cns.12092. Epub 2013 Apr 10.

PMID:
23575351
3.

Isolation and characterization of cancer stem like cells in human glioblastoma cell lines.

Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, You QD, Guo QL.

Cancer Lett. 2009 Jun 28;279(1):13-21. doi: 10.1016/j.canlet.2009.01.016. Epub 2009 Feb 15.

PMID:
19232461
4.

Selective lentiviral gene delivery to CD133-expressing human glioblastoma stem cells.

Bayin NS, Modrek AS, Dietrich A, Lebowitz J, Abel T, Song HR, Schober M, Zagzag D, Buchholz CJ, Chao MV, Placantonakis DG.

PLoS One. 2014 Dec 26;9(12):e116114. doi: 10.1371/journal.pone.0116114. eCollection 2014.

5.

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G.

Clin Cancer Res. 2009 Jul 1;15(13):4299-311. doi: 10.1158/1078-0432.CCR-08-1883. Epub 2009 Jun 9.

6.

CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.

Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R.

Cancer Biol Ther. 2010 Dec 1;10(11):1182-90. Epub 2010 Dec 1.

PMID:
20948317
7.

Brain tumor stem cells from an adenoid glioblastoma multiforme.

Oka N, Soeda A, Noda S, Iwama T.

Neurol Med Chir (Tokyo). 2009 Apr;49(4):146-50; discussion 150-1.

8.

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.

Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL.

J Neurooncol. 2009 Aug;94(1):1-19. doi: 10.1007/s11060-009-9919-z. Epub 2009 May 26.

9.

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.

Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA, McFarlane N, Subapanditha M, Nolte SM, Singh M, Bakhshinyan D, Garg N, Vijayakumar T, Lach B, Provias JP, Reddy K, Murty NK, Doble BW, Bhatia M, Hassell JA, Singh SK.

Clin Cancer Res. 2015 Dec 1;21(23):5324-37. doi: 10.1158/1078-0432.CCR-14-3147. Epub 2015 Jul 7.

10.

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, Elsässer-Beile U, Niedermann G.

Cancer Res. 2015 Jun 1;75(11):2166-76. doi: 10.1158/0008-5472.CAN-14-2415. Epub 2015 Apr 3.

11.

Targeting EGFRvIII for glioblastoma multiforme.

Yang J, Yan J, Liu B.

Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23. Review.

PMID:
28649003
12.

CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.

Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G, Iezzi G.

Stem Cells Transl Med. 2012 Aug;1(8):592-603. doi: 10.5966/sctm.2012-0003. Epub 2012 Aug 6.

13.

Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme.

Wang J, Wang X, Jiang S, Lin P, Zhang J, Wu Y, Xiong Z, Ren JJ, Yang H.

Cell Mol Neurobiol. 2008 Nov;28(7):991-1003. doi: 10.1007/s10571-008-9273-2. Epub 2008 Mar 19.

PMID:
18350379
14.

Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.

Brown DV, Daniel PM, D'Abaco GM, Gogos A, Ng W, Morokoff AP, Mantamadiotis T.

Oncotarget. 2015 Mar 20;6(8):6267-80.

15.

Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29.

16.

Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Stockhausen MT, Kristoffersen K, Stobbe L, Poulsen HS.

Cancer Biol Ther. 2014 Feb;15(2):216-24. doi: 10.4161/cbt.26736. Epub 2013 Nov 1.

17.

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.

18.

CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity.

Shi CJ, Gao J, Wang M, Wang X, Tian R, Zhu F, Shen M, Qin RY.

World J Gastroenterol. 2011 Jun 28;17(24):2965-71. doi: 10.3748/wjg.v17.i24.2965.

19.

Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.

Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K.

Clin Cancer Res. 2012 Apr 1;18(7):1901-13. doi: 10.1158/1078-0432.CCR-11-3084. Epub 2012 Feb 7.

20.

CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.

Bexell D, Gunnarsson S, Siesjö P, Bengzon J, Darabi A.

Int J Cancer. 2009 Jul 1;125(1):15-22. doi: 10.1002/ijc.24306.

Supplemental Content

Support Center